Part D Utilization Management

Imperial Health Plan of California (HMO) (HMO SNP) (IHP) applies a number of Quality Assurance and Utilization Management Initiatives that are designed to improve quality, prevent over- and under-utilization and reduce costs. These programs include but are not limited to Medication Therapy Management, Concurrent Drug Utilization Review, and Retrospective Drug Utilization.

CONCURRENT DRUG REVIEW

IHP has policies and procedures designed to ensure that a review of the prescribed drugs is performed at the point of sale or distribution before a prescription is dispensed to a member. IHP, through its Pharmacy Benefits Manager EnvisionRx, promotes appropriate dispensing and use of drugs to ensure high quality of care and cost-effective therapy.

On-line reviews or edits include but are not limited to:

- Duplicate Drug Class
- Drug Age/Gender Edit
- Over/Under utilization
- Incorrect Drug Dosage/Duration of Therapy
- Drug-to-Disease Contraindication
- Drug/Allergy Edits

This program is not considered a benefit.

RETROSPECTIVE DRUG UTILIZATION

IHP utilizes a retrospective Drug Utilization Review (DUR). The Drug Utilization Review (DUR) is designed to provide ongoing periodic examination of claims data and other records through a computerized drug claims and information retrieval system. The system being used to identify patterns of inappropriate or medically unnecessary drug use associated with specific drugs or groups of drugs.

These DUR reviews include but are not limited to the following:

- Alerts to prescribers on drug related therapy problems.
- Brand and Generic drug utilization with provision of alternative ways to improve costs.
- Physician utilization reports that identify over/under utilization, patterns of prescribing, poly-pharmacy patients.

This program is not considered a benefit.